Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib
Ronan Swords, Devalingam Mahalingam, Swaminathan Padmanabhan, Jennifer Carew, Francis GilesInstitute for Drug Development, Cancer Therapy and Research Centre, University of Texas Health Science Centre at San Antonio, USAAbstract: Chronic myeloid leukemia (CML) is the consequence of a single balanced...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2009-03-01
|
| Series: | Drug Design, Development and Therapy |
| Online Access: | http://www.dovepress.com/nilotinib-optimal-therapy-for-patients-with-chronic-myeloid-leukemia-a-a3002 |